Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(75%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(3)

Detailed Status

Terminated3
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

enrolling_by_invitation125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

NCT03846193
terminatedphase_2

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04566445
terminatedphase_2

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04437368
enrolling_by_invitationphase_2

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827

Clinical Trials (4)

Showing 4 of 4 trials
NCT03846193Phase 1

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Terminated
NCT04566445Phase 2

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Terminated
NCT04437368Phase 2

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Terminated
NCT05481827Phase 2

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Enrolling By Invitation

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4